The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Diazyme Laboratories sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Diazyme Laboratories Inc (Diazyme Laboratories) is a diagnostic reagents developer. The company offers test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, diabetes, and electrolytes. It offers products by markers, instrument specific packaging, point of care, DZ lite instrument, analyzer parameters, data sheets. Diazyme Laboratories offers anemia markers, cancer markers, cardiovascular markers, coagulation markers, diabetic markers, electrolyte markers, inflammatory markers, liver markers, renal and pancreatic marker, sepsis marker and vitamin marker. The company’s technology comprise enzyme cycling technology, latex enhanced immunoassay and FemtoQuant technology. Diazyme Laboratories is headquartered in Poway, California, the US. Key subsidiaries of Diazyme Laboratories include Diazyme Europe.
The key metrics of Diazyme Laboratories related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Diazyme Laboratories is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Diazyme Laboratories.
For a detailed understanding of the performance of Diazyme Laboratories, buy the report here.